A new initiative on precision medicine.N. Engl. J. Med. 2015; 372: 793-795
- Coyne G.O.
- Takebe N.
- Chen A.P.
Defining precision: the precision medicine initiative trials NCI-MPACT and NCI-MATCH.Curr. Probl. Cancer. 2017; 41: 182-193
Next-generation sequencing in the clinic: promises and challenges.Cancer Lett. 2013; 340: 284-295
- Nature. 2011; 474: 609-615
The changing view of high-grade serous ovarian cancer.Cancer Res. 2012; 72: 2701-2704
New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances.Clin. Cancer Res. 2014; 20: 5150-5156
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.Clin. Cancer Res. 2008; 14: 5198-5208
Whole-genome characterization of chemoresistant ovarian cancer.Nature. 2015; 521: 489-494
BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.Am. J. Pathol. 2010; 177: 1611-1617
Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.Clin. Cancer Res. 2014; 20: 6618-6630
Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.Oncotarget. 2015; 6: 37663-37677
Integrated genomic characterization of endometrial carcinoma.Nature. 2013; 497: 67-73
Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies.Gynecol. Oncol. 2015; 139: 118-126
Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.Gynecol. Oncol. 2016; 143: 168-178
Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies.J. Obstet. Gynaecol. Res. 2016; 42: 757-762
The genetic landscape of endometrial clear cell carcinomas.J. Pathol. 2017; 243: 230-241
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.Cancer. 2013; 119: 3776-3783
An overview of the NCI precision medicine trials-NCI Match and MPACT.Chin. Clin. Oncol. 2015; 4: 31
- Flaherty K.T.
- Chen A.P.
- O'Dwyer P.J.
- Conley B.A.
- Hamilton S.R.
- Williams M.
- Gray R.J.
- Li S.
- McShane L.M.
- Rubinstein L.V.
- Lee S.I.
- Lin F.I.
- Caimi P.F.
- Nemcek Jr., A.A.
- Mitchell E.P.
- Zwiebel J.A.
NCI-Molecular analysis for therapy choice (NCI-MATCH or EAY131).Natl. Cancer Inst. 2016; : 1-27
Tumor BRCA1 reversion mutation arising during neoadjuvant platinum-based chemotherapy in triple-negative breast cancer is associated with therapy resistance.Clin. Cancer Res. 2017; 23: 3365-3370
Hallmarks of cancer: the next generation.Cell. 2011; 144: 646-674
Expression of VEGF and HIF-1alpha in locally advanced cervical cancer: potential biomarkers for predicting preoperative radiochemotherapy sensitivity and prognosis.Onco Targets Ther. 2016; 9: 3031-3037
Incorporation of bevacizumab in the primary treatment of ovarian cancer.N. Engl. J. Med. 2011; 365: 2473-2483
A phase 3 trial of bevacizumab in ovarian cancer.N. Engl. J. Med. 2011; 365: 2484-2496
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.J. Clin. Oncol. 2012; 30: 2039-2045
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.Gynecol. Oncol. 2015; 139: 10-16
- Pujade-Lauraine E.
- et al.
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial.J. Clin. Oncol. 2014; 32: 1302-1308
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2017; 18: 779-791
Improved survival with bevacizumab in advanced cervical cancer.N. Engl. J. Med. 2014; 370: 734-743
The role of Cediranib in ovarian cancer.Expert. Opin. Pharmacother. 2017; 18: 1637-1648
- Ntanasis-Stathopoulos I.
- et al.
The emerging role of tyrosine kinase inhibitors in ovarian cancer treatment: a systematic review.Cancer Investig. 2016; 34: 313-339
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet. 2016; 387: 1066-1074
A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: an NRG oncology/gynecologic oncology group study.Gynecol. Oncol. 2015; 138: 507-512
- Ame J.C.
- Spenlehauer C.
- de Murcia G.
The PARP superfamily.BioEssays. 2004; 26: 882-893
The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings.Mol. Oncol. 2011; 5: 387-393
Trapping of PARP1 and PARP2 by clinical PARP inhibitors.Cancer Res. 2012; 72: 5588-5599
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.Gynecol. Oncol. 2016; 140: 199-203
- Pujade-Lauraine E.
- et al.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Oncol. 2017; 18: 1274-1284
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.J. Clin. Oncol. 2015; 33: 244-250
- Lee L.
- Gupta M.
- Sahasranaman S.
Immune checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy.J. Clin. Pharmacol. 2016; 56: 157-169
- Le D.T.
- Smith K.N.
- et al.
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science. 2017; 357: 409-413
Safety and antitumor activity of Pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study.J. Clin. Oncol. 2017; 35: 2535-2541
Intratumor heterogeneity: evolution through space and time.Cancer Res. 2012; 72: 4875-4882
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.N. Engl. J. Med. 2012; 366: 883-892
Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity.Mol. Oncol. 2015; 9: 967-996
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.J. Pathol. 2013; 231: 21-34
- Tannock I.F.
- Hickman J.A.
Limits to personalized cancer medicine.N. Engl. J. Med. 2016; 375: 1289-1294
Perspective: the precision-oncology illusion.Nature. 2016; 537: S63